tiprankstipranks
Scholar Rock Holding (SRRK)
NASDAQ:SRRK
US Market
SRRK
Scholar Rock Holding
RESEARCH TOOLSreports

Scholar Rock Holding (SRRK) Stock Forecast & Price Target

536 Followers
See the Price Targets and Ratings of:

SRRK Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Scholar
Rock Holding
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SRRK Stock 12 Month Forecast

Average Price Target

$57.80
▲(15.83% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Scholar Rock Holding in the last 3 months. The average price target is $57.80 with a high forecast of $70.00 and a low forecast of $50.00. The average price target represents a 15.83% change from the last price of $49.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","71":"$71","38.75":"$38.8","49.5":"$49.5","60.25":"$60.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,38.75,49.5,60.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.35,50.93846153846154,52.526923076923076,54.11538461538461,55.70384615384616,57.292307692307695,58.88076923076923,60.46923076923077,62.05769230769231,63.64615384615385,65.23461538461538,66.82307692307693,68.41153846153847,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.35,50,50.65,51.3,51.95,52.6,53.25,53.9,54.55,55.199999999999996,55.849999999999994,56.5,57.15,{"y":57.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.35,49.4,49.45,49.5,49.550000000000004,49.6,49.65,49.7,49.75,49.8,49.85,49.9,49.95,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.06,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.05,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.61,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$57.80Lowest Price Target$50.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on SRRK
Etzer Darout
Barclays
Barclays
$53
Buy
6.21%
Upside
Reiterated
04/01/26
Analysts' Top Healthcare Picks: Sotera Health (SHC), Insmed (INSM)
Jefferies Analyst forecast on SRRK
Amy Li
Jefferies
Jefferies
$57
Buy
14.23%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK) and Medtronic (NYSE: MDT)
H.C. Wainwright Analyst forecast on SRRK
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$58
Buy
16.23%
Upside
Reiterated
03/31/26
Apitegromab: Strengthened Regulatory Position and Dual-Site Strategy De-Risk Approval and Commercialization
Citi Analyst forecast on SRRK
Geoff Meacham
Citi
Citi
$58
Buy
16.23%
Upside
Reiterated
03/31/26
De-Risked Regulatory Path and Manufacturing Readiness Underpin Buy Rating on Apitegromab
Bank of America Securities Analyst forecast on SRRK
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$51→$58
Buy
16.23%
Upside
Reiterated
03/31/26
Scholar Rock price target raised to $58 from $51 at BofAScholar Rock price target raised to $58 from $51 at BofA
Raymond James Analyst forecast on SRRK
Martin Auster
Raymond James
Raymond James
$53→$60
Buy
20.24%
Upside
Reiterated
03/30/26
Scholar Rock price target raised to $60 from $53 at Raymond JamesScholar Rock price target raised to $60 from $53 at Raymond James
Wedbush Analyst forecast on SRRK
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$50→$56
Buy
12.22%
Upside
Reiterated
03/20/26
Wedbush Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
Truist Financial Analyst forecast on SRRK
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/20/26
Analysts Are Bullish on These Healthcare Stocks: Viatris (VTRS), Scholar Rock Holding (SRRK)
Cantor Fitzgerald Analyst forecast on SRRK
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
03/19/26
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT), Scholar Rock Holding (NASDAQ: SRRK) and Acrivon Therapeutics, Inc. (NASDAQ: ACRV)
BMO Capital Analyst forecast on SRRK
Evan Seigerman
BMO Capital
BMO Capital
$70
Buy
40.28%
Upside
Reiterated
03/18/26
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)
J.P. Morgan Analyst forecast on SRRK
Tessa Romero
J.P. Morgan
J.P. Morgan
$50
Buy
0.20%
Upside
Assigned
03/16/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and Scholar Rock Holding (NASDAQ: SRRK)
Piper Sandler Analyst forecast on SRRK
Allison Bratzel
Piper Sandler
Piper Sandler
$51→$58
Buy
16.23%
Upside
Reiterated
03/04/26
Piper Sandler Keeps Their Buy Rating on Scholar Rock Holding (SRRK)
TD Cowen Analyst forecast on SRRK
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
03/04/26
Analysts' Top Healthcare Picks: Scholar Rock Holding (SRRK), Alcon (ALC)
UBS Analyst forecast on SRRK
Michael Yee
UBS
UBS
$60
Buy
20.24%
Upside
Initiated
01/07/26
Scholar Rock initiated with a Buy at UBSScholar Rock initiated with a Buy at UBS
Wolfe Research Analyst forecast on SRRK
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
$42
Buy
-15.83%
Downside
Initiated
11/17/25
Scholar Rock initiated with an Outperform at Wolfe ResearchScholar Rock initiated with an Outperform at Wolfe Research
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on SRRK
Etzer Darout
Barclays
Barclays
$53
Buy
6.21%
Upside
Reiterated
04/01/26
Analysts' Top Healthcare Picks: Sotera Health (SHC), Insmed (INSM)
Jefferies Analyst forecast on SRRK
Amy Li
Jefferies
Jefferies
$57
Buy
14.23%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK) and Medtronic (NYSE: MDT)
H.C. Wainwright Analyst forecast on SRRK
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$58
Buy
16.23%
Upside
Reiterated
03/31/26
Apitegromab: Strengthened Regulatory Position and Dual-Site Strategy De-Risk Approval and Commercialization
Citi Analyst forecast on SRRK
Geoff Meacham
Citi
Citi
$58
Buy
16.23%
Upside
Reiterated
03/31/26
De-Risked Regulatory Path and Manufacturing Readiness Underpin Buy Rating on Apitegromab
Bank of America Securities Analyst forecast on SRRK
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$51→$58
Buy
16.23%
Upside
Reiterated
03/31/26
Scholar Rock price target raised to $58 from $51 at BofAScholar Rock price target raised to $58 from $51 at BofA
Raymond James Analyst forecast on SRRK
Martin Auster
Raymond James
Raymond James
$53→$60
Buy
20.24%
Upside
Reiterated
03/30/26
Scholar Rock price target raised to $60 from $53 at Raymond JamesScholar Rock price target raised to $60 from $53 at Raymond James
Wedbush Analyst forecast on SRRK
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$50→$56
Buy
12.22%
Upside
Reiterated
03/20/26
Wedbush Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)
Truist Financial Analyst forecast on SRRK
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/20/26
Analysts Are Bullish on These Healthcare Stocks: Viatris (VTRS), Scholar Rock Holding (SRRK)
Cantor Fitzgerald Analyst forecast on SRRK
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
03/19/26
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT), Scholar Rock Holding (NASDAQ: SRRK) and Acrivon Therapeutics, Inc. (NASDAQ: ACRV)
BMO Capital Analyst forecast on SRRK
Evan Seigerman
BMO Capital
BMO Capital
$70
Buy
40.28%
Upside
Reiterated
03/18/26
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)
J.P. Morgan Analyst forecast on SRRK
Tessa Romero
J.P. Morgan
J.P. Morgan
$50
Buy
0.20%
Upside
Assigned
03/16/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Resmed (NYSE: RMD) and Scholar Rock Holding (NASDAQ: SRRK)
Piper Sandler Analyst forecast on SRRK
Allison Bratzel
Piper Sandler
Piper Sandler
$51→$58
Buy
16.23%
Upside
Reiterated
03/04/26
Piper Sandler Keeps Their Buy Rating on Scholar Rock Holding (SRRK)
TD Cowen Analyst forecast on SRRK
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
03/04/26
Analysts' Top Healthcare Picks: Scholar Rock Holding (SRRK), Alcon (ALC)
UBS Analyst forecast on SRRK
Michael Yee
UBS
UBS
$60
Buy
20.24%
Upside
Initiated
01/07/26
Scholar Rock initiated with a Buy at UBSScholar Rock initiated with a Buy at UBS
Wolfe Research Analyst forecast on SRRK
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
$42
Buy
-15.83%
Downside
Initiated
11/17/25
Scholar Rock initiated with an Outperform at Wolfe ResearchScholar Rock initiated with an Outperform at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Scholar Rock Holding

3 Months
xxx
Success Rate
7/11 ratings generated profit
64%
Average Return
+45.81%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +45.81% per trade.
1 Year
Allison BratzelPiper Sandler
Success Rate
12/13 ratings generated profit
92%
Average Return
+93.91%
Copying Allison Bratzel's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +93.91% per trade.
2 Years
xxx
Success Rate
12/13 ratings generated profit
92%
Average Return
+161.27%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +161.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRRK Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
4
0
0
1
1
Buy
16
22
14
29
20
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
22
14
30
21
In the current month, SRRK has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SRRK average Analyst price target in the past 3 months is 57.80.
Each month's total comprises the sum of three months' worth of ratings.

SRRK Financial Forecast

SRRK Earnings Forecast

Next quarter’s earnings estimate for SRRK is -$0.80 with a range of -$0.91 to -$0.63. The previous quarter’s EPS was -$0.88. SRRK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SRRK has Performed in-line its overall industry.
Next quarter’s earnings estimate for SRRK is -$0.80 with a range of -$0.91 to -$0.63. The previous quarter’s EPS was -$0.88. SRRK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SRRK has Performed in-line its overall industry.

SRRK Sales Forecast

Next quarter’s sales forecast for SRRK is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SRRK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SRRK has Performed in-line its overall industry.
Next quarter’s sales forecast for SRRK is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SRRK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SRRK has Performed in-line its overall industry.

SRRK Stock Forecast FAQ

What is SRRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Scholar Rock Holding’s 12-month average price target is 57.80.
    What is SRRK’s upside potential, based on the analysts’ average price target?
    Scholar Rock Holding has 15.83% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SRRK a Buy, Sell or Hold?
          Scholar Rock Holding has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Scholar Rock Holding’s price target?
            The average price target for Scholar Rock Holding is 57.80. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $50.00. The average price target represents 15.83% Increase from the current price of $49.9.
              What do analysts say about Scholar Rock Holding?
              Scholar Rock Holding’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of SRRK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.